Raymond James Turns Bullish On ProQR

 

• Raymond James upgraded ProQR Therapeutics N.V. 
  PRQR+5.51%+ Free Alerts
   to Outperform based on a high conviction that "RNA editing" emerges as an impactful field of therapeutics in coming years. 
• The analyst notes that targets are plentiful, including Alpha-1-antitrypsin deficiency, on which Raymond James based the new model (assume this will be one of five programs partnered with Eli Lilly And Co 
  LLY+2.22%+ Free Alerts
   with peak royalties of $150 million.
• During initiating the coverage, the analyst said to own PRQR for RNA editing alone but got blown up after disappointing Phase 3 sepofarsen data. 
• "Now is our opportunity to own and defend that call, which we are doing with conviction," says Raymond James analyst.
• The company makes a bet easier with deprioritization of everything else besides axiomer.

https://www.benzinga.com/general/biotech/22/08/28478144/raymond-james-bullish-on-this-penny-stocks-reprioritized-pipeline